Literature DB >> 7756050

The short- and long-term effects of methotrexate on the rat skeleton.

D L Wheeler1, R A Vander Griend, T J Wronski, G J Miller, E E Keith, J E Graves.   

Abstract

Both clinical and laboratory studies have shown that the chemotherapy drug, Methotrexate (MTX), has adverse short-term effects on bone. There are no studies that demonstrate the long-term response of bone to MTX. The purpose of this study was to determine the short- and long-term effects of MTX on bone volume, turnover, mineralization and strength. Three-month-old Sprague-Dawley rats were randomly assigned to a control (CTL) or MTX group and were given either daily MTX or saline injections for two separate 5-day courses (5 on/9 off/5 on). Fluorochrome compounds were injected prior to killing to label actively mineralizing bone surfaces. One CTL and MTX group were killed at 30, 80 and 170 days after treatment. Both femurs and tibiae were harvested for cancellous and cortical bone histomorphometry and biomechanical testing (torsion). Standard cancellous and cortical histomorphometric parameters were measured from undecalcified, methyl-methacrylate-embedded sections from the right proximal tibia and tibial and femoral diaphyses. The contralateral femur and tibia were torsionally loaded to failure and standard mechanical parameters were measured. All bone responses were statistically analyzed using a two-way ANOVA followed by Duncan's multiple comparison procedure (significance: p = 0.05). Cancellous bone volume was significantly lower in the MTX-treated group at 80 and 170 days. Cancellous mineralizing surface and longitudinal bone growth were significantly depressed at all time points yet mineral apposition rate was only depressed at the 170-day point. Cancellous osteoclast surface was increased at all time points for the MTX-treated animals.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7756050     DOI: 10.1016/8756-3282(94)00032-u

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  22 in total

Review 1.  Skeletal complications of breast cancer therapies.

Authors:  Angela Hirbe; Elizabeth A Morgan; Ozge Uluçkan; Katherine Weilbaecher
Journal:  Clin Cancer Res       Date:  2006-10-15       Impact factor: 12.531

2.  Pegylated interferon α/ribavirin therapy enhances bone mineral density in children with chronic genotype 4 HCV infection.

Authors:  Ahmed Megahed; Nanees Salem; Abeer Fathy; Tarik Barakat; Mona Abd El Latif Alsayed; Suzy Abd El Mabood; Khaled R Zalata; Ahmed F Abdalla
Journal:  World J Pediatr       Date:  2017-01-27       Impact factor: 2.764

Review 3.  Juvenile rheumatoid arthritis: therapeutic perspectives.

Authors:  Ian C Chikanza
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 4.  Methotrexate osteopathy: five cases and systematic literature review.

Authors:  F Robin; S Cadiou; J-D Albert; G Bart; G Coiffier; P Guggenbuhl
Journal:  Osteoporos Int       Date:  2020-10-30       Impact factor: 4.507

5.  Osteonecrosis of the Jaw in the Absence of Antiresorptive or Antiangiogenic Exposure: A Series of 6 Cases.

Authors:  Tara L Aghaloo; Sotirios Tetradis
Journal:  J Oral Maxillofac Surg       Date:  2016-07-30       Impact factor: 1.895

Review 6.  Can bone loss in rheumatoid arthritis be prevented?

Authors:  M Vis; M Güler-Yüksel; W F Lems
Journal:  Osteoporos Int       Date:  2013-06-18       Impact factor: 4.507

Review 7.  Osteoporosis drug therapy strategies in the setting of disease-modifying agents for autoimmune disease.

Authors:  B F Ricciardi; J Paul; A Kim; L A Russell; J M Lane
Journal:  Osteoporos Int       Date:  2012-09-07       Impact factor: 4.507

Review 8.  Skeletal manifestations of treatment of breast cancer.

Authors:  Palak Choksi; Margaret Williams; Patricia M Clark; Catherine Van Poznak
Journal:  Curr Osteoporos Rep       Date:  2013-12       Impact factor: 5.096

9.  Prevention of bone growth defects, increased bone resorption and marrow adiposity with folinic acid in rats receiving long-term methotrexate.

Authors:  Chia-Ming Fan; Bruce K Foster; Susanta K Hui; Cory J Xian
Journal:  PLoS One       Date:  2012-10-05       Impact factor: 3.240

10.  Bone mineral density deficits in childhood cancer survivors: Pathophysiology, prevalence, screening, and management.

Authors:  Min Jae Kang; Jung Sub Lim
Journal:  Korean J Pediatr       Date:  2013-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.